Physician profile
Kaitlin Christopherson
NPI 1245627926
$684.85
in general payments reported to CMS, 2019-2025
13 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $40.89 · 2023: $115 · 2024: $213 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $280.71 | 2022-2025 | Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $101.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.75 | 2025 | |
| Teleflex LLC | $45.84 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2025 | Fruzaqla |
| Blue Earth Diagnostics | $26.27 | 2025 | Posluma |
| Merck Sharp & Dohme LLC | $26.02 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $25.04 | 2025 | |
| Telix Pharmaceuticals | $24.74 | 2024 | Illuccix |
| Daiichi Sankyo INC. | $20.70 | 2025 | Vanflyta |
| Dendreon Pharmaceuticals LLC | $17.94 | 2024 | Provenge |
| Pfizer INC. | $17.08 | 2024 | |
| Genentech USA, INC. | $17.06 | 2024 | Phesgo, Itovebi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Christopherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.